Dipharma Acquires LogixX Pharma in UK Deal
Swiss drugmaker Dipharma completes acquisition of UK rare-disease marketer LogixX Pharma, which becomes a wholly owned subsidiary.
Updated on Nov. 6, 2026 in Healthcare
Dipharma has completed its acquisition of UK-based LogixX Pharma, bringing the company into the Dipharma Group as a wholly owned subsidiary. LogixX will keep its name and continue operating under Michael Close's leadership.
Why it matters
The deal gives Dipharma a direct commercial presence in the United Kingdom and establishes LogixX as a platform for future product launches there. It formalizes a partnership that has run for nearly ten years.
LogixX, founded in 2010, has served as Dipharma's UK commercial partner for nearly ten years and has distributed sapropterin dihydrochloride for the company since 2023. The financial terms of the acquisition were not disclosed.
The players
Dipharma Group
Dipharma is a Switzerland-based pharmaceutical company that develops and markets medicines, including nitisinone, and is now expanding its direct presence in the UK.
LogixX Pharma
LogixX Pharma is a UK specialty pharmaceutical company headquartered in Theale, Berkshire, focused on rare and metabolic disease medicines.
Michael Close
Michael Close leads LogixX Pharma and will continue to direct the company under its existing name following the acquisition.
The details
LogixX specializes in marketing medicines for rare and metabolic diseases in the UK and supplies the National Health Service and homecare providers. Its fertility business, now operating as a separate company, was excluded from the deal.
Timeline
Nearly ten years before the acquisition: LogixX became Dipharma's UK commercial partner.
2010: LogixX was founded.
2023: LogixX began distributing sapropterin dihydrochloride for Dipharma.
6 November 2026: Acquisition completion was reported.
Market Landscape
The acquisition reflects a broader pattern in which pharmaceutical manufacturers bring specialty rare-disease distributors into their corporate groups rather than relying on third-party partners. Such moves give manufacturers direct control over launches and pricing in national markets such as the UK.
For patients with rare metabolic conditions in the UK, the acquisition is intended to support a more stable supply and a broader therapy pipeline through LogixX's NHS and homecare channels. Patients and providers are not expected to see immediate changes in existing treatments from the extraction alone.
The takeaway
Direct ownership of distribution partners is becoming a more common route for drugmakers seeking durable footholds in national markets. Watch whether the combined company broadens its UK rare-disease portfolio as integration proceeds.
Further reading
For broader context on pharmaceutical industry deals, explore more in Healthcare.
Source note: This article includes information reported by Manufacturingchemist.
